MARATTO

article · Expert Opinion on Therapeutic Patents

Patents involving monoamine oxidase (MAO): a comprehensive update (2022–2025) on its inhibitors and applications

Abstract

Recently patented MAO inhibitors show notable properties, including significant isoform selectivity and therapeutic potential toward other diseases, such as fibromyalgia, CDKL5-deficient disorder, neuropathic pain, and Alzheimer's disease.

Research topics

  • Parkinson's Disease Mechanisms and Treatments
  • Neurotransmitter Receptor Influence on Behavior
  • Phosphodiesterase function and regulation

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1080/13543776.2026.2633345

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.